Allurion Technologies (NYSE:ALUR) is a medical technology company specializing in non-surgical weight-loss solutions. The company’s flagship product, the Allurion Gastric Balloon, is a swallowable, fluid-filled device designed to promote weight loss by creating a sense of fullness in the stomach. Unlike traditional intragastric balloons, the Allurion device does not require endoscopic insertion or removal, as it self-deflates and is naturally expelled after treatment, simplifying the patient experience and reducing clinical resource requirements.
In addition to its gastric balloon, Allurion has developed a comprehensive digital health platform that integrates wireless tracking devices, a mobile application, and remote coaching to support patients throughout their weight-loss journey. The platform provides real-time data on body composition, dietary intake, and physical activity, enabling healthcare providers to monitor patient progress and tailor interventions accordingly. This holistic approach combines medical devices with data-driven behavioral support.
Founded in the early 2010s and headquartered in Natick, Massachusetts, Allurion Technologies has expanded its operations globally, offering its weight-loss solution in multiple markets across North America, Europe, the Middle East, and Asia. The company collaborates with physicians, hospitals, and wellness centers to deliver its programs and has secured regulatory approvals in key jurisdictions, including CE mark certification and other local clearances. Allurion’s strategic partnerships with clinics and healthcare networks aim to make non-surgical weight management more accessible to a wider patient population.
Allurion Technologies continues to invest in research and development to advance its product pipeline and digital offerings. By combining minimally invasive medical devices with a connected health ecosystem, the company seeks to address the growing challenge of obesity and related metabolic conditions through scalable, patient-centric solutions.
